{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:47:05Z","timestamp":1791658025993,"version":"4.3.4"},"reference-count":53,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":389,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jacc.2024.12.030","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T18:53:21Z","timestamp":1737140001000},"page":"1189-1203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Anticoagulation and Antiplatelet Therapy\u00a0for Atrial Fibrillation and Stable Coronary Disease"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0146-5611","authenticated-orcid":false,"given":"Sina","family":"Rashedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Keykhaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-5276","authenticated-orcid":false,"given":"Gregory","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Eikelboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9860-3584","authenticated-orcid":false,"given":"Marc P.","family":"Bonaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Shizuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1456-6430","authenticated-orcid":false,"given":"Felicita","family":"Andreotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8214-3010","authenticated-orcid":false,"given":"Laurent","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-262X","authenticated-orcid":false,"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9163-724X","authenticated-orcid":false,"given":"David J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnood","family":"Bikdeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jacc.2024.12.030_bib1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.advms.2017.06.005","article-title":"Patients with atrial fibrillation and coronary artery disease - Double trouble","volume":"63","author":"Michniewicz","year":"2018","journal-title":"Adv Med Sci"},{"issue":"1","key":"10.1016\/j.jacc.2024.12.030_bib2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamainternmed.2013.11912","article-title":"Atrial fibrillation and the risk of myocardial infarction","volume":"174","author":"Soliman","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.jacc.2024.12.030_bib3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacc.2024.12.030_bib4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.jacc.2024.12.030_bib5","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the\u00a0management of patients with chronic coronary\u00a0disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"36","key":"10.1016\/j.jacc.2024.12.030_bib6","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jacc.2024.12.030_bib7","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/eurheartj\/ehad781","article-title":"Atrial fibrillation in chronic coronary syndromes: a neglected challenge","volume":"45","author":"Hatala","year":"2024","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.jacc.2024.12.030_bib8","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.jacc.2024.12.030_bib9","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCULATIONAHA.118.036768","article-title":"Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation: OAC-ALONE Study. Article","volume":"139","author":"Matsumura-Nakano","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.12.030_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5905022","article-title":"Edoxaban monotherapy in nonvalvular atrial fibrillation patients with coronary artery disease","volume":"2022","author":"Fukamachi","year":"2022","journal-title":"J\u00a0Interv Cardiol"},{"issue":"22","key":"10.1016\/j.jacc.2024.12.030_bib11","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa2407362","article-title":"Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease","volume":"391","author":"Cho","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jacc.2024.12.030_bib12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10840-022-01347-1","article-title":"Dual therapy with oral anticoagulation and single antiplatelet agent versus monotherapy with oral anticoagulation alone in patients with atrial fibrillation and stable ischemic heart disease: a systematic review and meta-analysis","volume":"66","author":"Shakir","year":"2023","journal-title":"J\u00a0Interv Card Electrophysiol"},{"issue":"10","key":"10.1016\/j.jacc.2024.12.030_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/clc.70026","article-title":"Meta-analysis comparing oral anticoagulant monotherapy versus dual antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease","volume":"47","author":"Ahmed","year":"2024","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacc.2024.12.030_bib14","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2024.12.030_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ahj.2022.01.014","article-title":"Edoxaban-based long-term antithrombotic therapy in patients with atrial fibrillation and stable coronary disease: rationale and design of the randomized EPIC-CAD trial. Article","volume":"247","author":"Cho","year":"2022","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.jacc.2024.12.030_bib16","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"issue":"11","key":"10.1016\/j.jacc.2024.12.030_bib17","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2024.12.030_bib18","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"issue":"9","key":"10.1016\/j.jacc.2024.12.030_bib19","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.jacc.2024.12.030_bib20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2021.02.012","article-title":"A\u00a0proposed framework to guide evidence synthesis practice for meta-analysis with zero-events studies","volume":"135","author":"Xu","year":"2021","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jacc.2024.12.030_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.socscimed.2017.05.049","article-title":"The \"Hispanic mortality paradox\" revisited: Meta-analysis and meta-regression of life-course differentials in Latin American and Caribbean immigrants' mortality","volume":"186","author":"Shor","year":"2017","journal-title":"Soc Sci Med"},{"issue":"3","key":"10.1016\/j.jacc.2024.12.030_bib22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jclinepi.2014.09.005","article-title":"Cochran's Q test was useful to assess heterogeneity in likelihood ratios in studies of diagnostic accuracy","volume":"68","author":"Cohen","year":"2015","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"11","key":"10.1016\/j.jacc.2024.12.030_bib23","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"7650","key":"10.1016\/j.jacc.2024.12.030_bib24","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"9526","key":"10.1016\/j.jacc.2024.12.030_bib25","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jacc.2024.12.030_bib26","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.288.19.2441","article-title":"Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis","volume":"288","author":"van Walraven","year":"2002","journal-title":"JAMA"},{"issue":"8202","key":"10.1016\/j.jacc.2024.12.030_bib27","first-page":"989","article-title":"A\u00a0double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group","volume":"2","year":"1980","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.jacc.2024.12.030_bib28","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/eurheartj\/ehr204","article-title":"Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology","volume":"32","author":"Steg","year":"2011","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.jacc.2024.12.030_bib29","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/j.jacc.2016.03.485","article-title":"DAPT score utility for risk prediction in patients with or without previous myocardial infarction","volume":"67","author":"Kereiakes","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacc.2024.12.030_bib30","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/eurheartj\/ehac515","article-title":"Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis","volume":"44","author":"Andreotti","year":"2023","journal-title":"Eur Heart J"},{"issue":"10206","key":"10.1016\/j.jacc.2024.12.030_bib31","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.jacc.2024.12.030_bib32","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.jacc.2024.12.030_bib33","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.jacc.2024.12.030_bib34","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jacc.2024.12.030_bib35","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/europace\/euz345","volume":"22","author":"Galli","year":"2020","journal-title":"Europace"},{"issue":"1","key":"10.1016\/j.jacc.2024.12.030_bib36","doi-asserted-by":"crossref","DOI":"10.1080\/09537104.2023.2176173","article-title":"Sex differences in antiplatelet therapy: state-of-the art","volume":"34","author":"Gasecka","year":"2023","journal-title":"Platelets"},{"issue":"1","key":"10.1016\/j.jacc.2024.12.030_bib37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamacardio.2019.4296","article-title":"Association of sex with outcomes in patients undergoing percutaneous coronary intervention: a subgroup analysis of the GLOBAL LEADERS Randomized Clinical Trial","volume":"5","author":"Chichareon","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"9678","key":"10.1016\/j.jacc.2024.12.030_bib38","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jacc.2024.12.030_bib39","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1001\/jamacardio.2021.1720","article-title":"Sex differences among patients with high risk receiving ticagrelor with or without aspirin after percutaneous coronary intervention: a subgroup analysis of the TWILIGHT randomized clinical trial","volume":"6","author":"Vogel","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.jacc.2024.12.030_bib40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/2047487317744363","article-title":"Age and gender differences in medical adherence after myocardial infarction: Women do not receive optimal treatment - the Netherlands claims database","volume":"25","author":"Eindhoven","year":"2018","journal-title":"Eur J Prev Cardiol"},{"issue":"9","key":"10.1016\/j.jacc.2024.12.030_bib41","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1055\/a-2278-8769","article-title":"Racial differences in ischemic and hemorrhagic stroke: an ecological epidemiological study","volume":"124","author":"Kang","year":"2024","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.jacc.2024.12.030_bib42","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/a-2269-1123","article-title":"Racial Differences in Bleeding Risk: An Ecological Epidemiological Study Comparing Korea and United Kingdom Subjects","volume":"124","author":"Kang","year":"2024","journal-title":"Thromb Haemost"},{"issue":"16","key":"10.1016\/j.jacc.2024.12.030_bib43","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jacc.2024.07.045","article-title":"Bivalirudin vs heparin anticoagulation in STEMI: confirmation of the BRIGHT-4 results","volume":"84","author":"Stone","year":"2024","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10366","key":"10.1016\/j.jacc.2024.12.030_bib44","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(22)01999-7","article-title":"Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial","volume":"400","author":"Li","year":"2022","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jacc.2024.12.030_bib45","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/eurheartj\/ehy807","article-title":"Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial","volume":"40","author":"Chao","year":"2019","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.jacc.2024.12.030_bib46","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1055\/s-0042-1750385","article-title":"Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific Expert Consensus Paper","volume":"122","author":"Gorog","year":"2022","journal-title":"Thromb Haemost"},{"issue":"15","key":"10.1016\/j.jacc.2024.12.030_bib47","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.113.004834","article-title":"Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study","volume":"129","author":"Lamberts","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.12.030_bib48","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijcard.2018.03.018","article-title":"Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation: \"OLTAT registry\"","volume":"264","author":"Fischer","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2024.12.030_bib49","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ijcard.2018.06.098","article-title":"Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries","volume":"270","author":"Patti","year":"2018","journal-title":"Int J\u00a0Cardiol"},{"issue":"10","key":"10.1016\/j.jacc.2024.12.030_bib50","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/clc.22750","article-title":"Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: association with ischemic and bleeding events","volume":"40","author":"Lemesle","year":"2017","journal-title":"Clin Cardiol"},{"issue":"36","key":"10.1016\/j.jacc.2024.12.030_bib51","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.jacc.2024.12.030_bib52","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jacc.2021.06.022","article-title":"Increasing participation of women in cardiovascular trials: JACC Council Perspectives","volume":"78","author":"Cho","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10292","key":"10.1016\/j.jacc.2024.12.030_bib53","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/S0140-6736(21)00684-X","article-title":"The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030","volume":"397","author":"Vogel","year":"2021","journal-title":"Lancet"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725000713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725000713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:53:10Z","timestamp":1774403590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725000713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0735109725000713"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2024.12.030","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulation and Antiplatelet Therapy\u00a0for Atrial Fibrillation and Stable Coronary Disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2024.12.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}